Advanced Liver Cancer Pipeline Summary

DelveInsight’s, “Advanced Liver Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Liver Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Liver Cancer: Understanding

Advanced Liver Cancer: Overview

Advanced liver cancer most commonly refers to advanced hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, characterized by unresectable disease, vascular invasion, extrahepatic metastases, or progression beyond the stage amenable to curative therapies. HCC usually develops in the setting of chronic liver disease and cirrhosis caused by hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease (MASLD).

Patients often present with abdominal pain, unexplained weight loss, fatigue, anorexia, abdominal fullness, jaundice, hepatomegaly, ascites, and declining liver function, although early disease may remain asymptomatic. Advanced-stage disease is associated with a poor prognosis due to tumor progression and underlying hepatic dysfunction. Treatment decisions depend on tumor burden, liver function, performance status, and the presence of vascular invasion or distant metastases.

The pathophysiology of advanced liver cancer involves progressive hepatocarcinogenesis driven by chronic inflammation, fibrosis, and genomic alterations that promote malignant transformation of hepatocytes. Persistent liver injury induces oxidative stress, hepatocyte regeneration, and accumulation of genetic and epigenetic abnormalities involving pathways such as TERT, TP53, CTNNB1 (?-catenin), PI3K/AKT/mTOR, VEGF, and Wnt/?-catenin, facilitating uncontrolled proliferation, angiogenesis, immune evasion, and metastasis.

Diagnosis is based on multiphasic contrast-enhanced CT or MRI, demonstrating characteristic arterial phase hyperenhancement with portal venous or delayed washout in at-risk patients, while serum alpha-fetoprotein (AFP) may support diagnosis and disease monitoring. Histopathological confirmation is recommended when imaging findings are atypical or the diagnosis remains uncertain. Disease staging is commonly performed using the Barcelona Clinic Liver Cancer (BCLC) system, which integrates tumor stage, liver function, and patient performance status to guide treatment.

Management of advanced liver cancer focuses on prolonging survival, controlling disease progression, and maintaining quality of life through systemic therapy. Current first-line treatment for eligible patients includes immune checkpoint inhibitor-based combinations, particularly atezolizumab plus bevacizumab or durvalumab plus tremelimumab (STRIDE regimen), which have demonstrated superior survival compared with sorafenib. For patients unsuitable for immunotherapy, targeted therapies such as lenvatinib or sorafenib remain important first-line options, while regorafenib, cabozantinib, ramucirumab (for AFP ?400 ng/mL), nivolumab, pembrolizumab, and ipilimumab plus nivolumab are used in selected later-line settings. Locoregional therapies, palliative radiotherapy, symptom-directed supportive care, and multidisciplinary management are integral to treatment, while ongoing clinical trials are evaluating novel immunotherapies, antibody-drug conjugates, cell therapies, and targeted agents to improve outcomes in advanced disease.

"Advanced Liver Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Liver Cancer pipeline landscape is provided which includes the disease overview and Advanced Liver Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Liver Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Liver Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Liver Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Liver Cancer.

Advanced Liver Cancer Emerging Drugs Chapters

This segment of the Advanced Liver Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Liver Cancer Emerging Drugs

TPST-1120: Tempest Therapeutics

TPST-1120 (amezalpat) is an investigational, first-in-class, orally administered PPAR? (peroxisome proliferator-activated receptor alpha) antagonist that targets tumor lipid metabolism, angiogenesis, and the immunosuppressive tumor microenvironment to enhance antitumor immunity. In advanced hepatocellular carcinoma (HCC), it is being evaluated in combination with atezolizumab and bevacizumab as a first-line treatment for patients with unresectable or metastatic disease. The ongoing Phase III, randomized, double-blind, placebo-controlled trial compares TPST-1120 plus atezolizumab/bevacizumab versus placebo plus atezolizumab/bevacizumab, with overall survival as the primary endpoint. The study aims to determine whether adding TPST-1120 improves survival, progression-free survival, and response rates while maintaining an acceptable safety profile.

HLX43: Shanghai Henlius Biotech

HLX43 is an investigational anti-PD-L1 antibody-drug conjugate (ADC) that delivers a DNA topoisomerase I inhibitor payload selectively to PD-L1-expressing tumor cells, aiming to enhance antitumor activity while limiting systemic toxicity. In advanced liver cancer (hepatocellular carcinoma, HCC), it is being evaluated as monotherapy in a Phase II, open-label, randomized, dose-finding study for patients with locally advanced or metastatic HCC who have failed or are intolerant to standard therapies. The trial is assessing the optimal dose along with efficacy, safety, and tolerability across multiple dosing cohorts.

TTI-101: Tvardi Therapeutics

TTI-101 is an investigational, orally administered STAT3 (Signal Transducer and Activator of Transcription 3) inhibitor designed to block STAT3 signaling involved in tumor growth, survival, angiogenesis, and immune evasion in hepatocellular carcinoma (HCC). It is currently being evaluated in the Phase Ib/II REVERT-Liver Cancer trial as both monotherapy and in combination with pembrolizumab or atezolizumab plus bevacizumab for patients with locally advanced, metastatic, or unresectable HCC. The study aims to determine the recommended Phase II dose, assess safety and tolerability, and evaluate preliminary antitumor efficacy, including objective response rate, progression-free survival, and pharmacokinetics.

TYRA-430: Tyra Biosciences

TYRA-430 is an investigational, orally administered, first-in-class, selective and reversible FGFR4/FGFR3 (fibroblast growth factor receptor 4/3) inhibitor designed to target tumors with activating FGF/FGFR pathway alterations, including hepatocellular carcinoma (HCC). It is being evaluated in the Phase I SURF431 trial in patients with locally advanced, unresectable, or metastatic HCC and other advanced solid tumors harboring FGF/FGFR pathway aberrations. The study aims to determine the maximum tolerated dose, recommended Phase II dose, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TYRA-430 as an oral monotherapy.

Further product details are provided in the report……..

Advanced Liver Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Liver Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Advanced Liver Cancer
• There are approx. 50+ key companies which are developing the therapies for Advanced Liver Cancer. The companies which have their Advanced Liver Cancer drug candidates in the most advanced stage, i.e. Phase III include, Tempest Therapeutics.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Advanced Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Liver Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Advanced Liver Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Liver Cancer drugs.

Advanced Liver Cancer Report Insights

• Advanced Liver Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Liver Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Liver Cancer drugs?
• How many Advanced Liver Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Liver Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Liver Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Liver Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tempest Therapeutics
• Shanghai Henlius Biotech
• Tyra Biosciences
• Tvardi Therapeutics
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• TransThera Sciences
• Zhejiang Haichang Biotech Co., Ltd.
• AstraZeneca
• Ascentawits Pharmaceuticals, Ltd
• GlaxoSmithKline
• TORL Biotherapeutics
• Iterion Therapeutics
• Qurgen Inc.
• Qilu Pharmaceutical Co., Ltd.
• Qurient Co., Ltd.
• Myeloid Therapeutics
• ModeX Therapeutics
• GV20 Therapeutics
• Etnova Therapeutics Corp
• Base Therapeutics

Key Products

• TPST-1120
• HLX43
• TYRA-430
• TTI-101
• SHR-8068
• TT-00420
• WGI-0301
• Volrustomig
• AST-3424
• TSR-022 and TSR-042
• TORL-4-500
• Tegavivint
• SON-DP
• QL1706
• Q702
• MT-303
• MDX2001
• GV20-0251
• ETN101
• NK521